In ALS, the loss of certain proteins turns off a gene called UNC13A that needs to stay active for nerve cell communication, a ...

Completing a project in her backyard was satisfying for columnist Kristin Neva, whose work as an ALS caregiver is repetitive and ongoing.

Patient randomization is nearly complete in Medicinova’s Phase 2b/3 COMBAT-ALS trial testing MN-166 (ibudilast) for the ...

Columnist Dagmar Munn feels as if she's finding her voice again as she picks up her speech exercises, and then some.

Answer ALS is backing a Louisiana collaboration aimed at using AI to accelerate drug discovery for ALS and other ...

AB Science's new Phase 3 trial of masitinib for ALS has been cleared to launch in certain European countries, as well as in ...

Patient randomization is nearly complete in Medicinova’s Phase 2b/3 COMBAT-ALS trial testing MN-166 (ibudilast) for the treatment of ALS.

Answer ALS is backing a Louisiana collaboration aimed at using AI to accelerate drug discovery for ALS and other neurodegenerative disorders.